ResMed Appoints BD's CFO to Board

By Bobby Samwell • Saturday, August 17 07:54 • Permanent Link

ResMed (NYSE: RMD, ASX: RMD) has announced the expansion of its board of directors to 11 members with the appointment of Christopher DelOrefice, the Chief Financial Officer of BD, one of the largest global MedTech companies in the world. DelOrefice brings over 30 years of strategic and operational finance expertise to ResMed's board.

Before joining BD in September 2021, DelOrefice served in various roles at Johnson & Johnson (J&J), including as vice president of investor relations and previously as CFO of J&J’s consumer and medical device business segments for North America. He also held roles in finance leadership for supply chain, corporate mergers and acquisitions, consumer research and development, and business development for J&J’s North America pharmaceutical business.

DelOrefice's appointment to ResMed's board is expected to complement the company's existing leadership with his financial experience in healthcare and medical technology at BD, J&J, and AstraZeneca. He holds a Master of Business Administration and a Bachelor of Science in Accounting from Villanova University and remains actively engaged in student career mentoring and development initiatives at his alma mater.

ResMed's expansion of its board of directors and the appointment of DelOrefice reflect the company's commitment to strengthening its leadership team with individuals who bring extensive experience and expertise in the healthcare and medical technology sectors. Today the company's shares have moved 0.2% to a price of $227.75. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.